

Use of Solventum™ AbThera™ Advance Open Abdomen Dressing for abdominal closure following colon resection and mucous fistula revision

Marc R. Matthews, MD, MS, FACS

Associate Director, Arizona Burn Center, Director, Burn Emergency Services, Director, Respiratory Care Services, Maricopa Medical Center, Clinical Associate Professor - Surgery, University of Arizona College of Medicine - Phoenix

Patient

A 69-year-old male presented to the Emergency Department (ED) with complaints of increasing constipation and abdominal pain. He was known to have metastatic adenocarcinoma of the sigmoid colon with near obstruction and recent weight loss of 24 lbs.

Diagnosis

A computed tomography (CT) scan revealed the sigmoid mass and worsening proximal obstruction with increased fecal load in the colon more proximal to the sigmoid mass. An attempt was made to deploy a colonic stent near the obstructing sigmoid malignancy after the gastrointestinal (GI) consultant placed a wire across the lesion. However, the colonic stent could not be applied given the tightness of the colonic structure. The patient was also noted to have a markedly distended abdomen and was taken to the operating room (OR) for an exploratory laparotomy.

Initial treatment/application of AbThera Advance Dressing

During the laparotomy, the patient had removal of ascites and decompression of his massively distended bowel. He also underwent resection of his transverse colon for multiple linear tears, a right-sided end colostomy and mucous fistula, which was followed by placement of AbThera Advance Dressing. Five laparotomy pads were left intra-abdominally, which were secondary to his coagulopathic state and peritoneal desmoplastic reaction. On postoperative day (POD) 2, he returned to the OR for abdominal re-exploration. The patient received a peritoneal washout, revision of the mucous fistula and maturation of the end colostomy, repacking of the abdomen with an absorbent hemostatic dressing (QuikClot Combat Gauze®; Z-MEDICA, LLC, Wallingford, CT) and the placement of a second AbThera Advance Dressing (Figure 1).

Figure 1. Open abdomen placement of AbThera Advance Dressing after colon resection and fistula revision.



A. Right lateral view of AbThera Advance Dressing placement and right-sided end colostomy.



B. Anterior view of open abdomen with AbThera Advance Dressing in between right-sided end colostomy and revised mucus fistula.



C. Left lateral view of AbThera Advance Dressing placement and revised mucus fistula.

Discharge and follow-up

On POD 4 the patient had another exploratory laparotomy, washout of the peritoneum, removal of the absorbent hemostatic dressing and fascial closure with size 0 poly(p-dioxanone) looped sutures (PDS-II® monofilament synthetic absorbable suture; Ethicon US, LLC, a Johnson & Johnson Company, Bridgewater, NJ) in a running fashion (Figure 2). By hospital day (HD) 23/POD 7 he was extubated, his nasogastric tube (NG tube) removed, and he received twice-a-day dressing changes to his open midline wound. Because of his metastatic disease with spinal involvement, he decided to be placed into hospice care. A swallow evaluation was pending at the time of discharge.

User experience

In this case, Solventum™ AbThera™ Advance Open Abdomen Dressing facilitated fascial closure of the abdomen and preempted the loss of abdominal domain.

Figure 2. Fascial closure of open abdomen after removal of AbThera Advance Dressing and laparotomy.



Photos and patient information courtesy of Dr. Marc R. Matthews, Maricopa Medical Center.

Note: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. This material is intended for healthcare professionals.

As with any case study, the results and outcomes of this patient should not be interpreted as a guarantee or warranty of similar results. Individual results may vary depending on the patient's circumstances and condition.

AbThera Advance Dressing is designed for use with the negative pressure wound therapy provided by the Solventum™ V.A.C.® Uta™ Therapy Unit. When using the V.A.C.® Uta Therapy Unit, do not select the Solventum™ Veraflo™ Instillation Therapy option. See Instructions for Use. Products described in this case study may not be available for sale in all markets as a result of local regulatory requirements. For information regarding product availability in your market, please contact your local Solventum representative.

©Solventum 2025. Solventum, the S logo, AbThera, and other trademarks are trademarks of Solventum or its affiliates. Other trademarks are the property of their respective owners.
70-2013-1052-4 PRA-PM-US-03163 (8/21)



Solventum Advanced Wound Care
12930 IH10 W
San Antonio, TX 78249
USA

Phone 800-275-4524
Web Solventum.com